このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Theratechnologies 将来の成長

Future 基準チェック /46

Theratechnologiesは、64.6%と17.4%でそれぞれ年率64.6%で利益と収益が成長すると予測される一方、EPSはgrowで66.8%年率。

主要情報

64.6%

収益成長率

66.8%

EPS成長率

Biotechs 収益成長	24.5%
収益成長率	17.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	03 Jun 2024

今後の成長に関する最新情報

Recent updates

Theratechnologies reports Q3 results, FY22 guidance on track

Oct 13

Theratechnologies stock gains on securing $100M term loan

Jul 13

業績と収益の成長予測

NasdaqCM:THTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
11/30/2026	113	22	32	30	4
11/30/2025	99	11	21	16	4
11/30/2024	88	0	6	-1	4
2/29/2024	78	-18	-6	-4	N/A
11/30/2023	82	-24	-7	-6	N/A
8/31/2023	80	-29	-7	-7	N/A
5/31/2023	80	-36	-16	-15	N/A
2/28/2023	81	-49	-14	-12	N/A
11/30/2022	80	-47	-16	-15	N/A
8/31/2022	77	-49	-19	-18	N/A
5/31/2022	74	-51	-19	-18	N/A
2/28/2022	73	-35	-18	-18	N/A
11/30/2021	70	-32	-18	-18	N/A
8/31/2021	70	-27	-15	-15	N/A
5/31/2021	66	-25	-12	-12	N/A
2/28/2021	66	-24	-14	-14	N/A
11/30/2020	66	-23	-14	-14	N/A
8/31/2020	63	-24	-11	-10	N/A
5/31/2020	65	-18	-5	-5	N/A
2/29/2020	64	-16	-13	-12	N/A
11/30/2019	63	-12	-7	-3	N/A
8/31/2019	61	-7	-21	2	N/A
5/31/2019	58	-5	-26	-3	N/A
2/28/2019	52	-4	-18	4	N/A
11/30/2018	45	-5	-19	0	N/A
8/31/2018	41	-7	-1	-1	N/A
5/31/2018	36	-9	-3	-3	N/A
2/28/2018	35	-15	0	0	N/A
11/30/2017	33	-14	N/A	2	N/A
8/31/2017	33	-11	N/A	3	N/A
5/31/2017	28	-8	N/A	3	N/A
2/28/2017	28	-1	N/A	4	N/A
11/30/2016	28	0	N/A	2	N/A
8/31/2016	27	1	N/A	2	N/A
5/31/2016	27	1	N/A	4	N/A
2/29/2016	25	2	N/A	5	N/A
11/30/2015	23	1	N/A	5	N/A
8/31/2015	18	-2	N/A	1	N/A
5/31/2015	12	-6	N/A	0	N/A
2/28/2015	8	-6	N/A	-4	N/A
11/30/2014	6	-9	N/A	-7	N/A
8/31/2014	5	-9	N/A	-6	N/A
5/31/2014	7	-7	N/A	-6	N/A
2/28/2014	7	-9	N/A	-6	N/A
11/30/2013	7	-4	N/A	-7	N/A
8/31/2013	10	-5	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: THTXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: THTX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: THTX今後 3 年以内に収益を上げることが予想されます。

収益対市場: THTXの収益 ( 17.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: THTXの収益 ( 17.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: THTXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Theratechnologies 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2024

Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2024

Theratechnologies Inc. Provides Earnings Guidance for the Year 2024

No longer forecast to breakeven

Theratechnologies Inc. Revises Revenue Guidance for the Fiscal Year of 2023

Forecast to breakeven in 2025

Recent updates

Forecast to breakeven in 2024

Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2024

Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee

Theratechnologies Inc. to Report Q1, 2024 Results on Apr 10, 2024

Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Inc., Annual General Meeting, May 09, 2024

Theratechnologies Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Theratechnologies Inc. Provides Earnings Guidance for the Year 2024

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Inc. to Report Q4, 2023 Results on Feb 21, 2024

Theratechnologies Inc. Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Theratechnologies Inc. Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Soleus Capital Management Engages in Discussions with Theratechnologies

Insufficient new directors

Theratechnologies Inc. announced that it has received $12.5 million in funding from Investissement Québec

Theratechnologies Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec

Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec

Theratechnologies Inc. Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

Theratechnologies Inc. Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Inc. Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA

Third quarter 2023 earnings: EPS exceeds analyst expectations

Theratechnologies Submits Tesamorelin F8 Formulation Sbla for Fda Review

Theratechnologies Inc. to Report Q3, 2023 Results on Sep 26, 2023

Theratechnologies Inc. Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide

New minor risk - Share price stability

Theratechnologies Completes 1-For-4 Reverse Stock Split to Regain Compliance with Nasdaq Listing Requirements

Theratechnologies Inc. Announces Resignation of Gary Littlejohn as Board of Directors and Member of Its Audit Committee

No longer forecast to breakeven

Theratechnologies Inc. Revises Revenue Guidance for the Fiscal Year of 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast to breakeven in 2025

Theratechnologies Inc. to Report Q2, 2023 Results on Jul 12, 2023

Theratechnologies Receives FDA Agreement to Amended Trial Protocol for Its Lead PDC Candidate Sudocetaxel Zendusortide

Theratechnologies Inc.'s Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Theratechnologies Inc. Announces Path to Resume TH1902 Clinical Development

Theratechnologies Inc. to Report Q4, 2022 Results on Feb 28, 2023

Theratechnologies Inc. Provides Revenue Guidance for the Fiscal Year 2022 and Fiscal Year 2023

Theratechnologies Inc. Provides Revenue Guidance for the Fiscal Year 2022 and Fiscal Year 2023

Theratechnologies Inc Announces Update from Ongoing TH1902 Study

Theratechnologies Reports Data Showing High Expression of Sortilin (Sort1) in Multiple Solid Tumors from Tissue Microarrays

Theratechnologies Inc. Re-Affirms Revenue Guidance for the Fiscal Year of 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Theratechnologies reports Q3 results, FY22 guidance on track

Theratechnologies’ Trogarzo® Approved by Fda for 30-Second Intravenous (Iv) Push, Simplifying Hiv Treatment for Heavily Treatment-Experienced Population

Theratechnologies Inc. to Report Q3, 2022 Results on Oct 13, 2022

Theratechnologies Inc. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth

Second quarter 2022 earnings: Revenues miss analyst expectations

Forecast to breakeven in 2024

Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2022

Theratechnologies stock gains on securing $100M term loan

Theratechnologies Inc. to Report Q2, 2022 Results on Jul 14, 2022

Theratechnologies Inc. Announces Elif Mcdonald as New Head of Investor Relations

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘